|
1.
|
|
20 p, 4.1 MB |
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
/
Palafox, Marta (Hospital Universitari Vall d'Hebron) ;
Monserrat, Laia (Hospital Universitari Vall d'Hebron) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Villacampa Javierre, Guillermo (Hospital Universitari Vall d'Hebron) ;
Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ibrahimi, Nusaibah (University Paris-Saclay) ;
Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ;
Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ;
Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ;
Òdena, Andreu (Hospital Universitari Vall d'Hebron) ;
Sánchez-Guixé, Mònica (Hospital Universitari Vall d'Hebron) ;
Capelán, Marta (Hospital Universitari Vall d'Hebron) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Bruna, Alejandra (The Institute of Cancer Research (Londres)) ;
Rodríguez, Olga (Hospital Universitari Vall d'Hebron) ;
Guzmán, Marta (Hospital Universitari Vall d'Hebron) ;
Grueso, Judit (Hospital Universitari Vall d'Hebron) ;
Viaplana, Cristina (Hospital Universitari Vall d'Hebron) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ;
Su, Faye (Novartis Pharmaceuticals) ;
Lin, Kui (Genentech, Inc., South San Francisco) ;
Clarke, Robert B. (Manchester Breast Centre) ;
Caldas, Carlos (Cancer Research UK) ;
Arribas, Joaquín V (Hospital Universitari Vall d'Hebron) ;
Michiels, Stefan (University Paris-Saclay) ;
García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ;
Turner, Nicholas C. (The Breast Cancer Now Research Centre) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ;
Dienstmann, Rodrigo (Hospital Universitari Vall d'Hebron) ;
Verma, Chandra S. (National University of Singapore) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Arnedos, Monica (Inserm Unit U981 (França)) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Serra, Violeta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. [...]
2022 -  10.1038/s41467-022-32828-6
Nature communications, Vol. 13 (september 2022)
|
|
|
2.
|
|
0 p, 567.1 KB |
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial
/
Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ;
Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ;
Lim, W.-T (National Cancer Centre Singapore) ;
de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ;
Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ;
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gottfried, M. (Oncology Institute of Meir Medical Center) ;
Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ;
Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ;
Wollner, M. (Rambam Health Care Campusm (Israel)) ;
Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ;
Vogel, A. (Hannover Medical School (Alemanya)) ;
Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ;
Akimov, Mikhail (Novartis Pharma (Siïssa)) ;
Ghebremariam, S. (Oncology Global Development-BDM) ;
Cui, X. (Novartis Institutes for Biomedical Research) ;
Nwana, N. (Oncology Precision Medicine) ;
Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ;
Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797
|
|
|
3.
|
|
1 p, 526.7 KB |
Author Correction : High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
/
Palafox, Marta (Vall d'Hebron Institut d'Oncologia) ;
Monserrat, Laia (Vall d'Hebron Institut d'Oncologia) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ;
Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ibrahimi, Nusaibah (University Paris-Saclay. Oncostat U1018, Inserm) ;
Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ;
Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ;
Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ;
Òdena, Andreu (Vall d'Hebron Institut d'Oncologia) ;
Sánchez-Guixé, Mònica (Vall d'Hebron Institut d'Oncologia) ;
Capelán, Marta (Hospital Universitari Vall d'Hebron) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Bruna, Alejandra (The Institute of Cancer Research. Preclinical Modelling of Pediatric Cancer Evolution Group) ;
Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Su, Faye (Novartis Pharmaceuticals) ;
Lin, Kui (Genentech, Inc., South San Francisco) ;
Clarke, Robert B. (Manchester Breast Centre) ;
Caldas, Carlos (Cancer Research UK) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Michiels, Stefan (University Paris-Saclay) ;
García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ;
Turner, Nicholas C. (The Breast Cancer Now Research Centre) ;
Prat, Aleix (IOB Institute of Oncology (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Verma, Chandra S. (National University of Singapore. Department of Biological Sciences) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center. Departments of Pathology and Human Oncology and Pathogenesis Program) ;
Arnedos, Monica (Inserm Unit U981) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
2022 - 10.1038/s41467-022-34580-3
Nature communications, Vol. 13 (november 2022)
|
|
|
4.
|
|
194 p, 5.1 MB |
1 Tesis Doctoral Selección de dosis en el desarrollo de fármacos para el tratamiento del cáncer en pacientes con insuficiencia renal y hepática
/
Azaro, Analía ;
Rodón Ahnert, Jordi, dir. ;
Valle, Marta, dir.
Els pacients amb cancer I insuficiència renal (IR) i/o insuficiencia hepática (IH) constitueixen un dels principals reptes en el tractament de el cáncer a causa que els fàrmacs antineoplàstics són pricipalment metabolizats pel fetge i eliminats pel ronyó i les dosis i esquemes de tractaments dels mateixos es van investigars, majoritàriament, en pacients amb funció renal i hepática normal. [...]
Los pacientes con cáncer e insuficiencia renal (IR) y/o insuficiencia hepática (IH) constituyen uno de los principales retos en el tratamiento del cáncer debido a que los fármacos antineoplásicos son principalmente metabolizados por el hígado y eliminados por el riñón y las dosis y esquemas de tratamientos de los mismos se investigaron, en su mayoría, en pacientes con función renal y hepática normal. [...]
Patients with cancer and renal impairment (RI) and /or hepatic impairment (HI) are one of the main challenges in cancer treatment since anti-cancer agents are mainly metabolized by the liver and eliminated by the kidneys and the doses and regimens for treatments were investigated mostly in patients with normal kidney and liver function. [...]
2021
|
|
|
5.
|
|
12 p, 435.5 KB |
Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts
/
Bang, Yung-Jue (Seoul National University College of Medicine) ;
Su, Wu-Chou (National Cheng Kung University Hospital) ;
Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ;
Nam, Do-Hyun (Samsung Medical Center) ;
Lim, Wan Teck (National Cancer Centre) ;
Bauer, Todd M. (PLLC) ;
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Poon, Ronnie Tung Ping (Queen Mary Hospital) ;
Hong, David (University of Texas/MD Anderson Cancer Center) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Akimov, Mikhail (Novartis Pharma AG) ;
Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ;
Zhao, Sylvia (China Novartis Institutes for Biomedical Research) ;
Giovannini, Monica (Novartis Pharmaceuticals Corporation) ;
Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547
|
|
|
6.
|
|
8 p, 500.8 KB |
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
/
Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ;
Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ;
Desaiah, Durisala (Eli Lilly and Company (USA)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Miles, Colin (Eli Lilly and Company (United Kingdom)) ;
Lahn, Michael M.. (Eli Lilly and Company (USA)) ;
Mitchell, Malcolm I (Eli Lilly and Company (USA)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303
|
|
|
7.
|
|
13 p, 501.3 KB |
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
/
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Machiels, Jean-Pascal (Institut Roi Albert II (Bèlgica). Department of Medical Oncology) ;
Rottey, Sylvie (Universitair Ziekenhuis Gent) ;
Damian, Silvia (National Cancer Institute of Milan) ;
Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ;
Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ;
Wack, Claudine (Sanofi, Chilly-Mazarin, France) ;
Shen, Liji (Sanofi, Bridgewater, NJ USA) ;
de Jonge, Maja (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197
|
|
|
8.
|
|
14 p, 1.9 MB |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
/
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ;
Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ;
Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Cleverly, Ann (Eli Lilly and Company) ;
Pillay, N. Sokalingum (Eli Lilly and Company) ;
Desaiah, Durisala (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ;
Blakeley, Jaishri (Johns Hopkins University) ;
Lahn, Michael M.. (Eli Lilly and Company) ;
Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
